Hemimegalencephaly and tuberous sclerosis complex: A rare yet challenging association

Eur J Paediatr Neurol. 2021 Jan:30:58-65. doi: 10.1016/j.ejpn.2020.12.007. Epub 2020 Dec 23.

Abstract

Hemimegalencephaly is a rare malformation of cortical development characterised by enlargement of one cerebral hemisphere. The association between hemimegalencephaly and tuberous sclerosis complex, an autosomal dominant genetic disorder, is uncommon and has so far been reported only in a few cases. Intractable epilepsy and severe developmental delay are typical clinical manifestations. Aberrant activation of the mTOR signalling pathway is considered to be the hallmark of the pathogenesis of these two disorders. Thus, mTOR inhibitors such as everolimus represent a promising therapeutic approach to mTOR-associated manifestations. We present a thorough literature review of the association between hemimegaloencephaly and tuberous sclerosis complex.

Keywords: Everolimus; Hemimegalencephaly; Malformations of cortical development; Tuberous sclerosis complex; mTOR inhibitors.

Publication types

  • Review

MeSH terms

  • Everolimus / therapeutic use
  • Hemimegalencephaly / complications*
  • Hemimegalencephaly / pathology
  • Humans
  • Male
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • Tuberous Sclerosis / complications*
  • Tuberous Sclerosis / genetics
  • Tuberous Sclerosis / pathology

Substances

  • Everolimus
  • MTOR protein, human
  • TOR Serine-Threonine Kinases